Interestingly, these authors demonstrated that snoRNAs were detectable in plasma, and three of them (SNORD33, SNORD66, SNORD76) showed higher plasma expressions in NSCLC patients compared with healthy control groups (P = 0.01), yielding a 81.1% sensitivity and 95.8% specificity in discriminating NSCLC from cancer-free individuals and patients affected by COPD [268]. This evidence concerns the gene SNORD33 and non-small cell lung carcinoma.